Clinical trial NCT05344248: Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing
Official title: A Randomized, Double Blinded, Multi-center, Placebo Controlled, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetic Profiles of Multiple Doses of JS005 in Patients With Moderate to Severe Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Moderate to Severe Psoriasis
Lead sponsor: Shanghai Junshi Bioscience Co., Ltd.
Sponsor class: OTHER
First posted: 2022-04-25
Enrollment: 183
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: JS005-002 is a randomized, double-blinded, placebo-controlled phase Ib/II clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of multiple doses of JS005 (recombinant humanized anti-IL-17A monoclonal antibody) Injection in patients with moderate to severe psoriasis.

Detailed description: This study includes a total of two parts, the first part is a double-blinded, placebo-controlled, multi-dose escalation study to evaluate the safety, preliminary efficacy and pharmacokinetic profiles after multiple doses in patients with moderate to severe psoriasis; the second part is a randomized, double-blinded, controlled study, with proposed high-, middle- and low-dose groups and placebo group based on the clinical effective dose determined in the first part, to evaluate the efficacy and safety of multiple doses of test drug in patients with moderate to severe psoriasis.

Part I of study (phase Ib):

A total of 4 dose groups are pre-specified in Part I of this study, i.e., 60 mg, 150 mg, 300 mg and 600 mg; multiple doses will be administered subcutaneously on abdomen. A total of 40 patients are planned to be enrolled, including 6 and 2 patients receiving test drug and placebo in 60 mg and 600 mg dose groups, respectively, 9 and 3 patients receiving test drug and placebo in the other two dose groups, respectively. Each patient can receive multiple doses at only one dose level.

Part II of study (phase II):

Based on the safety data of phase Ib study and the efficacy analysis of ER modeling, 300mg and 150mg of the test drug will be selected. A multi-center, double-blind, placebo-controlled phase II study was conducted. The patients will be radomized in a 1:1:1 ratio to receive 300mg, 150mg doses of the study drug or placebo. A total of 126 patients will be enrolled in phase II study, with 42 patients in each group. 300mg, 150mg doses of the study drug or placebo will be administered abdominal subcutaneously with multiple dosing. Each patient can receive multiple doses at only one dose level.

Eligibility criteria: Inclusion criteria:

1. Male and female patients aged 18 \~ 75 years (inclusive, age limited to 18 \~ 60 years in Part I of the study);
2. Body mass index (BMI) = weight (kg)/ height 2 (m2), ranging from 18\~30 kg/m2 (inclusive) at screening;
3. Being able to understand the content of the study and voluntary to sign the informed consent form; meanwhile, being able to complete the study as required in the protocol;
4. Having been diagnosed as chronic plaque psoriasis for at least 6 months prior to screening;
5. Being eligible for systemic therapy. Defined as moderate to severe chronic plaque psoriasis poorly controlled with local therapy and/or phototherapy and/or previous systemic therapy;
6. At screening, moderate to severe plaque psoriasis will be defined as followings: PASI score ≥ 12, PGA score ≥ 3 (in accordance with 0 \~ 5-point scale), and body surface area (BSA) affected by plaque psoriasis ≥10%;
7. No plan of pregnancy and being willing to use effective contraceptive measures for patients (including partners) from signature of informed consent to 6 months after administration of investigational product, see Appendix 7 for the specific contraceptive measures.

Exclusion criteria:

1. Prior biologic therapy (Secukinumab or Ixekizumab) that directly targets il-17 monoclonal antibody or IL-17 receptor at any time;
2. Use of a therapeutic biologic within 12 weeks prior to screening, or random administration of the drug during the elimination phase (5 half-lives), whichever is longer;
3. Participated in any other clinical study with investigational drug intervention within 12 weeks prior to screening, or the investigational drug was in the elimination phase (5 half-lives) at the time of randomization, whichever is longer;
4. Have received live vaccine within 12 weeks prior to screening, or plan to receive live vaccine within 12 weeks after administration of the last experimental drug;
5. Any infection requiring hospitalization, antiviral or antibiotic treatment within 30 days prior to screening (such as pneumonia, cellulitis, bone and joint infection, etc., and the investigator determined that the patient had low immune function and participation in this study might lead to unacceptable risks);
6. Received systemic treatment of Chinese herbal medicine for psoriasis within 30 days or external medication for psoriasis within 14 days prior to screening;
7. Have received systemic treatment for psoriasis within 30 days prior to screening or were using a prohibited treatment at the time of screening.As UV exposure is one of the contraindication treatments, patients who do not wish to limit their UV exposure (e.g., sunbathing and/or using tanning devices) during the study period will be excluded;
8. Non-chronic plaque psoriasis (e.g. Pustular psoriasis, erythrodermic psoriasis and intravenous psoriasis) at the time of screening;
9. Drug psoriasis (new or aggravated psoriasis caused by beta blockers, calcium channel inhibitors or lithium) at the time of screening;
10. The presence of other skin problems (e.g. skin infection, seborrheic dermatitis, severe allergic skin disease, etc.) that may interfere with the evaluation of psoriasis;
11. A history of inflammatory bowel disease, Crohn's disease, or other persistent active autoimmune disease;
12. Have a history of Tubercle bacillus (TB) infection, or chest imaging examination suggested TB infection during screening, or tuberculosis screening suggested latent tuberculosis infection;
13. History of transplantation of vital organs (such as heart, lung, liver, kidney, etc.);
14. A history or symptoms of malignancy in any organ system at the time of screening, whether or not it has been treated within the past 5 years, and whether or not there are signs of local recurrence or metastasis;
15. Having other significant medical problems at the time of screening, including, but not limited to, uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥95mmHg), congestive heart failure (New York heart association status class III or IV);
16. Medical history and past history suggest other major diseases, including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular diseases. The researcher considers that participation in this study would pose unacceptable risks to patients or significantly affect the study results;
17. Has undergone any major surgery within 8 weeks prior to screening, or is required to undergo such surgery during the study period, which the investigator and sponsor have confirmed may pose unacceptable risks to the patients;
18. Patients with serum creatinine above the upper limit of normal at screening time.Platelet \& LT during screening;100 x109/L, neutrophils \&lt;1.5x109 /L, or hemoglobin \&lt;85g/L, ALT or AST level increased ≥ 2 times the upper limit of normal value;
19. Abnormal electrocardiogram during screening was considered clinically significant by the investigator, and participation in the study may bring unacceptable risks to the patients;
20. At the time of screening, HBV DNA copy number was detected in persons who were positive for human immunodeficiency virus antibody (ANTI-HIV), hepatitis C virus antibody (anti-HCV), hepatitis B surface antigen (HBsAg) or HBcAb (upper limit of reference value of each hospital for quantitative test line);
21. Known to suffer from moderate to severe allergic diseases or hypersensitivity reactions;
22. Known history of allergy or hypersensitivity to study drugs, other monoclonal antibodies and therapeutic protein preparations (human serum albumin, cytokines, interleukins, etc.);
23. Screening and randomization of female patients with β -human Chorionic Gonadotropin (β-HCG) positivity or breastfeeding;
24. Blood loss or blood donation within the last 3 months \& GT;400mL, or patients who had received blood transfusion, or who planned to donate blood during the study;
25. Any other conditions considered unsuitable for study participation by the investigator, such as patients with other potential compliance problems, inability to complete all examinations and evaluations as required by the protocol, or uncontrolled neuropsychiatric or psychological disorders, present uncontrollable risks of study participation.

Primary outcomes:
measure: the numbers of adverse event(AE)
timeFrame: 0-24 weeks
measure: II: The proportion of patients with at least PASI 75 at Week 12
timeFrame: From week 0 to week 12
Secondary outcomes:
measure: Ib: PK evaluation: Cmax
timeFrame: 0-24 weeks
measure: Ib: PD evaluation: level of IL-17A
timeFrame: 0-24 weeks
measure: Ib: PASI score response criteria
timeFrame: 0-24 weeks
measure: Ib: Proportion of Patients achieving PASI 75
timeFrame: 0-24 weeks
measure: Ib: Proportion of Patients achieving PASI 90/100
timeFrame: 0-24 weeks
measure: Ib: Proportion of patients with PGA score
timeFrame: 0-12 weeks
measure: Ib: Mean change from baseline in body surface area (BSA)
timeFrame: 0-24 weeks
measure: Ib: Proportion of patients with DLQI score
timeFrame: 0-24 weeks
measure: Ib: Time to ADA occurrence after drug administration
timeFrame: 0-24 weeks
measure: Ib: Time to Nab occurrence after drug administration.
timeFrame: 0-24 weeks
measure: II: Proportion of Patients achieving PASI 90
timeFrame: 0-20 weeks
measure: II: Proportion of patients with PGA score
timeFrame: 0-20 weeks
measure: II: Patients achieving PASI 75
timeFrame: 0-20 weeks
measure: II: PASI score response criteria
timeFrame: 0-20 weeks
measure: II: PASI and/or with PGA score response criteria
timeFrame: 0-20 weeks
measure: II: BSA response criteria
timeFrame: 0-20 weeks
measure: Proportion of patients with DLQI score
timeFrame: 0-20 weeks
measure: II: The numbers of adverse event(AE).
timeFrame: 0-20 weeks
measure: II: PK evaluation: Cmax
timeFrame: 0-20 weeks
measure: II: PD evaluation: IL-17A
timeFrame: 0-20 weeks
measure: II: Time to ADA occurrence after drug administration.
timeFrame: 0-20 weeks
measure: Ib:PK evaluation: AUC0-inf
timeFrame: 0-24 weeks
measure: Ib: Percentage of patients with positive ADA after drug administration.
timeFrame: 0-24 weeks
measure: Ib: Percentage of patients with positive Nab after drug administration.
timeFrame: 0-24 weeks
measure: II: PK evaluation: AUC0-inf
timeFrame: 0-20 weeks
measure: II: Percentage of patients with positive ADA after drug administration.
timeFrame: 0-20 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese PLA General Hospital
state: Beijing
city: Beijing
country: China
facility: Peking University People's Hospital
state: Beijing
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Tsinghua Changgung Hospita
state: Beijing
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
state: Chongqing
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
state: Guangdong
city: Guangzhou
country: China
facility: Dermatology Hospital of Southern Medical University
state: Guangdong
city: Shijiazhuang
country: China
facility: The First Hospital of Hebei Medical University
state: Hebei
city: Haerbin
country: China
facility: Second Affiliated Hospital of Harbin Medical University
state: Heilongjiang
city: Nanjing
country: China
facility: Dermatology Hospital, Chinese Academy of Medical Sciences
state: Jiangsu
city: Zhenjiang
country: China
facility: Affiliated Hospital of Jiangsu University
state: Jiangsu
city: Nanchang
country: China
facility: The Second Affiliated Hospital of Nanchang University
state: Jiangxi
city: Changchun
country: China
facility: First Hospital of Jilin University
state: Jilin
city: Jinan
country: China
facility: Dermatology Hospital affiliated to Shandong First Medical University
state: Shandong
city: Jinan
country: China
facility: Qilu Hospital of Shandong University
state: Shandong
city: Shanghai
country: China
facility: Ruijin Hospital, Shanghai Jiaotong University School of Medicine
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Skin Disease Hospital
state: Shanghai
city: Taiyuan
country: China
facility: The First Affiliated Hospital of Shanxi Medical University
state: Shanxi
city: Tianjin
country: China
facility: Tianjin Medical University General Hospital
state: Tianjin
city: Tianjin
country: China
facility: Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine
state: Tianjin
city: Hangzhou
country: China
facility: The First Affiliated Hospital of Zhejiang University School of Medicine
state: Zhejiang
city: Hangzhou
country: China
facility: Zhejiang Provincial People's Hospital
state: Zhejiang
Study officials:
References: